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The purpose of the study was to combine the advantages of self-nanoemulsifying drug delivery systems 
and tablets as a conventional dosage form. Self-nanoemulsifying drug delivery system (SNEDDS) was 
prepared to enhance the solubility and thus oral bioavailability of sertraline. Aqueous titration method 
was used to prepare the liquid SNEDDS; ternary phase diagrams were constructed and based on smaller 
droplet size (24.8 nm), minimum viscosity (153.63 cP) and polydispersity index (0.182), higher percentage 
transmittance (95%) and in vitro drug release (97%), an optimum system was designated. Liquid SNEDDS 
was transformed into free-flowing powder by solid adsorption technique followed by compression into 
tablets. In vitro release of sertraline from liquid and solid SNEDDS was found to be highly significant 
compared to plain sertraline (p<0.01). Pharmacokinetic studies after oral administration of liquid and solid 
SNEDDS in rats showed about 6-and 5-fold increased absorption of sertraline compared to the aqueous 
suspension of sertraline. These studies demonstrate that the solid SNEDDS are promising strategies for 
successful delivery of poorly water-soluble drug like sertraline. 
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INTRODUCTION
Sertraline (SRT) free base (Figure 1) is lipophilic (log 
P, 5.1), poorly water-soluble drug (3.5 mg/L) belonging 
to the category “Selective Serotonin Reuptake Inhibitors 
(SSRIs)” commercially available as hydrochloride salt 
with around 44% oral bioavailability. Sertraline was found 
to be safer than other SSRIs, work better than fluoxetine 
for some subtypes of depression (Flament et al., 1999), 
reported as most prescribed antidepressant in U.S. retail 
market in 2007. Modification of the physicochemical 
properties such as salt formation of the compound is in 
practice as one of the approach to improve the dissolution 
rate of such drugs. But in general, these methods have their 
own limitations. For instance, salt formation of neutral 
compound is not feasible, and the synthesis of weak acid 
and weak base salts may not always be practical. Moreover, 
the salts that are formed may convert back to their 
original acid or base forms leading to aggregation in the 
gastrointestinal tract (GIT) leads to slow/poor absorption 
(Serajuddin, 1999). This may be the possible reason for 
poor oral bioavailability of sertraline hydrochloride. Also, 
the salt formation needs extra expenditure of revenue in 
the form of processing cost. 
Scientific attention has been made in recent years on 
lipid-based formulations to improve oral bioavailability 
of poorly water-soluble drug compounds (Humberstone, 
Charman, 1997). The most popular approach is the 
incorporation of the active constituents into inert lipid 
vehicles such as oils, surfactant and surfactant dispersions 
(Nielsen, Petersen, Ilertz, 2008), liposomes (Schwendener, 
Schott, 1996), emulsions (Kararli et al., 1992), self-
FIGURE 1 - Chemical structure of sertralin free base.
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emulsifying (Pouton, 1997) and self-microemulsifying 
formulations (Shen, Zhong, 2006) with particular 
emphasis on self-nanoemulsifying drug delivery systems 
(Gursoya, Benita, 2004). SNEDDS comprises of isotropic 
mixtures of natural, semisynthetic or synthetic oils with 
surfactants usually with one or more hydrophilic co-
solvents or co-emulsifiers. These systems spontaneously 
emulsify when diluted to gastrointestinal fluids to form 
oil-in-water (o/w) nanoemulsion having droplet size 
less than 100 nm (Mou et al., 2008; Porter et al., 2008). 
Furthermore, SNEDDS would be an efficient, convenient 
and more patient compliant approach in comparison to 
o/w nanoemulsion, as SNEDDS can be filled in hard 
gelatin capsules due to their anhydrous nature enabling 
its administration as unit dosage form (Date, Nagarsenker, 
2007; Rao, Shao, 2008).
Generally, SNEDDS are either administered as 
liquid dosage forms, encapsulated either in hard or soft 
gelatin capsules, transformed into granules/pellets and 
finally into tablets. Lipid formulations however may 
interact with the capsule shell resulting in either brittleness 
or softness of the shell. To address this limitation, liquid 
lipid formulations can be transformed into free-flowing 
powder by loading the formulation on a suitable solid 
carrier/transformed into granules/pellets (Rahman et al., 
2011). SNEDDS loaded powder/granules/pellets, however 
should have acceptable flow properties to facilitate capsule 
or tablet manufacturing in order to pass compendial limit 
for content uniformity and weight variation. It is a fact 
that solid dosage forms are preferred more than liquid 
preparations for many reasons including: facility of 
manufacturing process, convenience to the patient, dose 
accuracy, and stability. Incorporation of lipid formulations 
into solid dosage forms combines the advantages of 
lipid based drug delivery systems with those of solid 
dosage forms thus overcoming the drawbacks of lipid 
formulations (Abbaspour, Makhmalzadeh, 2014; Rashid 
et al., 2015).
Thus, the objective of the present study was to 
develop and characterize an optimal stable solid SNEDDS 
of sertraline using minimum surfactant concentration, so 
that nano-sized droplets could be maintained on dilution 
by the gastrointestinal (GI) fluids with an aim to increase 
its oral bioavailability. 
MATERIAL AND METHODS
Material
Sertraline was received as gift sample from R&D 
division, Ranbaxy, Gurgaon, India. LauroglycolTM 90 
(Propylene glycol monolaurate Type II; monoesters > 
90%, C12 (lauric acid) > 95%), Labrafil® M 2125 CS 
(Linoleoyl polyoxyl-6 glycerides; Oleic (C18:1) 24-34%, 
Linoleic (C18:2) 53-63%), MaisineTM 35-1 (Glyceryl 
monolinoleate; C18:2 >50%; C18:1 10-35%; C18:0 
<6%; C16 4-20%) were obtained from Gattefosse Corp. 
(France). Polyoxy 40 hydrogenated castor oil (Cremophor 
RH40) and polyoxy-35 castor oil (Cremophor EL) was 
obtained from BASF Co. (India). Sodium Starch Glycolate 
was obtained from Thomas baker (Mumbai, India). 
Magnesium stearate was obtained from Loba Chemie Pvt 
Ltd, (Mumbai, India). Transparent empty hard gelatin 
capsules were obtained as gift sample from Associated 
Capsules Ltd. (Mumbai, India). Other chemicals were of 
HPLC or analytical grade.
Methods
Solubility studies
The solubility of sertraline was ascertained in 
oils, surfactants and cosurfactants. An excess amount 
of sertraline was added to 2 mL of selected lipophile 
separately in stoppered vials and mixed with the help of 
vortex mixer. The vials were kept at 30 °C in an isothermal 
shaker (Nirmal International, Delhi, India) for 48 hours 
to reach equilibrium and then centrifuged at 3000 rpm for 
10 minutes. The supernatant was filtered through 0.22 μm 
filter for analysis of sertraline.
HPLC analysis of sertraline in vitro and in vivo
The solubility of sertraline in various excipients 
was determined by a validated in-house HPLC method. 
The apparatus consisted of Shimadzu model equipped 
with quaternary LC-10AVP pumps, variable wavelength 
programmable UV/VIS detector, SPD-10AVP column 
oven (Shimadzu), SCL 10AVP system controller 
(Shimadzu), Rheodyne injector fitted with a 20 µL loop 
and Class-VP 5.032 software. Mobile phase consisted of 
methanol/phosphate buffer (70:30 %v/v) at 1.25 mL/min 
flow rate, detection at 273 nm with retention time at 7.05 
min. The same method was used to quantify dissolution 
samples and amount of sertraline in plasma after oral 
administration of optimized formulations and aqueous 
suspension of plain drug. 
Preliminary screening of surfactant and cosurfactant
For  the  sc reening  of  su i tab le  sur fac tan t , 
emulsification ability was determined according to the 
method described (Date, Nagarsenker, 2007). Briefly, a 
fixed amount of Labrasol, Cremophor RH40, Cremophor 
EL, and Acconon CC-6 were mixed with the same 
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quantity of the oily phase. The mixtures were gently 
heated at 50 °C in water bath for homogenization of the 
components. Each mixture, 25 mg was then diluted with 
distilled water to 25 mL in a stoppered conical flask. 
Ease of emulsification was judged by the number of 
flask inversions required to yield homogenous emulsion. 
Emulsions were allowed to stand for 12 h and their % 
transmittance was evaluated by UV spectrophotometer 
using distilled water as a blank. Emulsions were 
furthermore observed visually for any turbidity or phase 
separation. The selected oily phase and surfactant were 
used for further screening of the different cosurfactants 
(Lauroglycol 90, Lauroglycol FCC, Caproyl 90, 
propylene glycol and polyethylene glycol) for their 
emulsification ability. Mixtures of 50 mg of cosurfactant, 
100 mg surfactant, and 200 mg oil were prepared and 
evaluated in a similar fashion as described above.
Construction of ternary phase diagram 
On the basis of the solubility study Labrafil M 2125 
CS [(LBF M 2125 CS) + Maisine 35-1)] in 1:1 ratio 
was selected as the oil phase. Labrasol and Cremophor-
EL were used as surfactants and Lauroglycol 90 as 
cosurfactant. Surfactant and cosurfactant (Smix) in each 
group were mixed in different volume ratios (1:0, 1:1, 
1:2, 1:3, 2:1, 3:1, 4:1). These Smix ratios were chosen in 
increasing concentration of cosurfactant with respect to 
surfactant and increasing concentration of surfactant with 
respect to cosurfactant for detailed study of the phase 
diagrams in nanoemulsion formation.
For each phase diagram, oil and specific Smix 
ratio were mixed thoroughly in different volume ratios 
from 1:9 to 9:1 in different glass vials. Sixteen different 
combinations of oil and Smix [1:9, 1:8, 1:7, 1:6, 1:5, 2:8 
(1:4), 1:3.5, 1:3, 3:7 (1:2.3), 1:2, 4:6 (1:1.5), 5:5 (1:1), 
6:4 (1:0.7), 7:3 (1:0.43), 8:2(1:0.25) and 9:1 (1:0.1)] were 
made so that maximum ratios were covered to delineate 
the boundaries of phases precisely formed in the phase 
diagrams. Pseudo-ternary phase diagrams were developed 
using aqueous titration method. Slow titration with 
aqueous phase was done to each volume ratio of oil and 
Smix and visual observation was carried out for transparent 
and easily flowable o/w nanoemulsions. The physical 
state of the nanoemulsion was marked on a pseudo-three-
component phase diagram with one axis representing 
aqueous phase, the other representing oil and the third 
representing a mixture of surfactant and cosurfactant at 
fixed volume ratios (Smix ratio). From each phase diagram 
constructed, different formulations were selected from the 
nanoemulsion region so that single dose of drug could be 
easily incorporated into the oil phase. 
Thermodynamic stability studies
To overcome the problem of metastable formulation, 
thermodynamic stability tests were performed by reported 
method (Shafiq et al., 2007a). Formulations were 
subjected to six cycles between refrigerator temperature 
(4 °C) and 40 °C with storage at each temperature of not 
less than 48 hours. Formulations which were stable at these 
temperatures were subjected to centrifugation test at 3500 
rpm for 30 min. Formulations that did not show any phase 
separation were again subjected to freeze thaw stress test 
between the temperature -21 °C and +25 °C. 
Dispersibility test 
The efficiency of self-emulsification was assessed 
using a standard USP XXII dissolution apparatus 2 (Khoo 
et al., 1998). 1 mL of each formulation was added to 500 
mL of distilled water, 0.1N HCl and 6.8 phosphate buffers 
(PB) at 37 ± 0.5 oC. A standard stainless-steel dissolution 
paddle rotating at 50 rpm provided gentle agitation. The 
in vitro performances of the formulations were visually 
assessed using the following grading system (Khoo et 
al., 1998, Shafiq et al., 2007b). A, denoting a rapidly 
forming (within 1 min) nanoemulsion which was clear 
or slightly bluish in appearance; B, denoting a rapidly 
forming, slightly less clear emulsion which had a bluish 
white appearance; C, denoting a bright white emulsion 
(similar in appearance to milk) that formed within 2 min; 
D, denoting a dull, grayish white emulsion with a slightly 
oily appearance that was slow to emulsify (longer than 2 
min); and E, denoting a formulation which exhibited either 
poor or minimal emulsification with large oil droplets 
present on the surface. 
Incorporation of drug in placebo formulations
From each group separately, one formulation was 
selected from each percent of oil (10, 15, 20 and 25%), 
having the least Smix concentration irrespective of Smix 
ratio used, but passing dispersebility test in Grade A 
or B only. 0.5 mL of formulation was prepared so that 
it can be easily filled into size #0 capsule. Formulation 
containing 10% of oil was excluded from the study 
because it just dissolves single dose of drug (i.e. 25 
mg) which is equal to the saturation solubility. 25 mg of 
sertraline was incorporated in each placebo formulation 
of oil mixture and respective Smix ratio and mixed with 
the help of vortex mixer. 
Interim stability study: Interim stability studies 
were carried out by keeping the sertraline incorporated 
formulations at 40 °C/75%RH. Physical appearance 
(precipitation or phase separation) was observed after 1 
month.
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Cloud point measurement
Developed SNEDDS were compared for cloud 
point value. Each formulation was diluted with water in 
the ratio of 1:100 and placed in a water bath with gradual 
increase in temperature. At the cloud point, the drop in 
sample % transmittance from the zero point was measured 
spectrophotometrically (Zhang et al., 2008).
Percentage transmittance
The optical clarity of SNEDDS formulations was 
measured spectroscopically upon dilution. Percentage 
transmittance was determined using Shimadzu UV 
spectrophotometer (Shimadzu, Japan). Formulations 
containing 25 mg of sertraline was diluted 100 times using 
double distilled water and analyzed at 500 nm.
Viscosity determination
The viscosity of the formulations (0.5 g) was 
determined without dilution using a Brookfield DV III 
ultra V6.0 RV cone and plate rheometer (Brookfield 
Engineering Laboratories, Inc, Middleboro, MA, spindle # 
CPE40) was used to determine the viscosity of developed 
formulations at 25 ± 1.0 °C. The software used for the 
calculations was Rheocalc V2.6.
Droplet size and polydispersity index 
The average droplet size and polydispersity index 
(PDI) of SNEDDS were measured by photon correlation 
spectroscopy (PCS) using a Malvern Zetasizer (Nano 
ZS90, Malvern instruments Ltd., UK) with a 50mV laser. 
The sensitivity range was 10 nm to 5 µm and the data were 
shown by computer calculation using the Mie equations 
of light scattering. The measurements were performed at 
25 °C at a fixed angle of 90°. The formulation (0.1 mL) 
was dispersed in 100 mL of water under gentle stirring in 
a glass beaker. 1 mL aliquot was withdrawn and added into 
a sample cell for droplet size measurement. 
In vitro release study
The in vitro release study was performed for the 
following objectives: to evaluate the sertraline release 
characteristic from developed SNEDDS and to compare 
the release relative to the plain sertraline. The studies were 
performed using dissolution apparatus II USP (DS 8000, 
Labindia, India) filled with 900 mL simulated gastric fluid 
(pH 1.2, without enzymes) as a dissolution media. The 
temperature was set at 37 ± 0.5 °C and speed of the paddle 
was maintained at 100 rpm. 5 mL of the samples were 
drawn out at the predetermined intervals and the same 
volume of fresh dissolution media was replenished. The 
samples were filtered through 0.22 µm Millipore filters 
and analyzed using validated in-house HPLC method and 
quantified as percentage using the following equation:
Development of solid SNEDDS
Adsorption on solid carriers 
The liquid SNEDDS was prepared by dissolving 25 
mg of sertraline in oils and mixing the required amounts 
of surfactant and cosurfactant using vortex mixer. 
Optimized liquid SNEDDS was then mixed with solid 
carriers (dibasic calcium phosphate, anhydrous lactose, 
calcium carbonate, magnesium carbonate and Aerosil 200) 
in different ratios (2:1, 1:1 and 1:2) by adding dropwise 
over it placed in a beaker. After each addition, the mixture 
was homogenized using glass rod to ensure uniform 
distribution of the droplet. The solid formulations obtained 
were passed through sieve number 22 to achieve uniformly 
free flowing self-nanoemulsifying granules (SNEG’s). The 
final blend of SNEG’s along with sodium starch glycolate 
(5%) and magnesium stearate (1%) were evaluated for 
various micromeritic properties viz. bulk density, tapped 
density, angle of repose, Carr’s Index and Hausner’s ratio. 
The final blend was compressed into tablet using single 
punch rotary compression machine; flat faced and die sized 
10 mm punch were used. 
Droplet size and polydispersity index of reconstituted 
nanoemulsion
Solid SNEDDS (100 mg) prepared were dispersed 
with 10 ml distilled water by vortex mixing and then 
incubated at 25 °C. Droplet size and polydispersity index 
of reconstituted nanoemulsion was assessed by photon 
correlation spectroscopy (Zetasizer 1000 HS, Malvern 
Instruments, UK). Light scattering was monitored at 25 °C 
at 90° angle. 
X-ray powder diffraction study
To verify the physical state of sertraline in solid 
SNEDDS, X-ray powder scattering measurements was 
carried out. A voltage of 40 kV and a current of 40 mA for 
the generator applied with Cu as the tube anode material. 
The solids exposed to a Cu-K radiation, over a range of 
2θ angles from 10-40o, at an angular speed of 2o (2θ)/min, 
a sampling interval of 0.02o /second.
In vivo study 
Approval to carry out in vivo study was obtained 
from Institutional animal ethics committee, Faculty of 
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Pharmacy, Integral University, and their guidelines were 
followed. The animals used for in vivo experiments were 
adult Sprague Dawley rats (SD rats) obtained from Central 
Drug Research Institute (CDRI), Lucknow, India.
The animals were kept under standard laboratory 
conditions, temperature at 25 ± 2 °C and relative humidity 
(55 ± 5%). The animals were housed in polypropylene 
cages, six per cage, with free access to standard laboratory 
diet and water. The formulations (LF3, powder blend of 
solid SNEDDS and plain sertraline) were given orally 
using oral feeding gauge. Dose for the rats was calculated 
based on the weight of the rats (2.25 mg of sertraline per kg 
body weight) according to the surface area ratio. The rats 
were anesthetized using ether and blood samples (0.5 mL) 
were withdrawn from the tail vein of rat at 0 (pre-dose), 
0.5, 1, 2, 4, 6, 8, 12, 24 and 36 h in microcentrifuge tubes in 
which 8 mg of EDTA was added as an anticoagulant. The 
blood collected was mixed with the anticoagulant properly 
and centrifuged at 5000 rpm for 20 min. The plasma was 
separated and stored at -21°C until drug analysis. 
Pharmacokinetic and statistical analysis
Pharmacokinetic parameters were calculated 
by noncompartmental analysis also called as Model 
independent analysis using WinNonLin version 4.0 
(Pharsight Corp., Mountain View, CA). Maximum 
concentration (Cmax) and time to reach maximum 
concentration (Tmax) are the values obtained directly from 
concentration–time curve. Area under the concentration–
time curve (AUC0→t) was also determined.
RESULTS AND DISCUSSION 
Solubility studies and selection of excipients
The solubility of sertraline was assessed in different 
oily phases alone and in combination, surfactant and 
cosurfactant (Figure 2). The solubility of the lipophilic 
drug sertraline was found to be highest in the combination 
of Labrafil M 2125 CS and Maisine 35-1 (1:1) ratio. 
Surfactants (Labrasol, Cremophor EL, Cremophor RH40 
and Acconon CC-6) had been selected for the study and 
solubility of sertraline was determined by the described 
method. Also, the surfactants were compared for their 
emulsification efficiencies using different oily phases. 
It has been reported that well formulated SNEDDS 
is dispersed within seconds under gentle stirring 
conditions. Transmittance values of different mixtures 
are demonstrated in Table I. Results inferred that the 
oily phase Labrafil M 2125 CS and Maisine 35-1 in 1:1 
ratio exhibited the highest emulsification efficiency with 
labrasol and Cremophor EL. Being non-ionic in nature, 
it has been considered that it is less toxic than ionic 
surfactants and are usually accepted for oral ingestion 
(Pouton, Porter, 2008). This encompasses effects on tight 
junction such as Labrasol (Hu et al., 2001), and inhibitory 
effects on p-glycoprotein (P-gp) and cytochrome P450 
enzymes such as Cremophor EL (Chen, 2008; Rahman 
et al., 2013).
Addition of a cosurfactant to the surfactant-
containing formulation was reported to improve 
dispersibility and drug absorption from the formulation 
(Lawrence, Rees, 2000). In view of current investigation, 
five cosurfactants, namely Lauroglycol 90, Lauroglycol 
FIGURE 2 - Solubility of sertraline in various oils, surfactants 
and cosurfactants.
TABLE I – Emulsification efficiency of various surfactants using different oily phases
Surfactant
% transmittance
Labrafil M 2125 CS Maisine 35-1
LBF M 2125 CS + 
Maisine (1:1) Labrafac
Labrasol 91.2 72 97.8 9
Cremophor EL 39.8 47.4 87 54
 Cremophor RH40 59 79.3 83 42.6
Acconon CC-6 8 21 42 14.3
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FCC, Caproyl 90, Propylene glycol and polyethylene 
glycol were compared. As depicted in Table II, the ratio 
of Labrafil M 2125 CS and Maisine 35-1 (1:1) exhibited 
good emulsification with cosurfactant Lauroglycol 90 
showing maximum transmittance of 97.4% and 95.4% 
with Labrasol and Cremophor EL, respectively. Herein, 
solubility of the drug in different cosurfactants may judge 
the final selection. Results of solubility study demonstrated 
highest solubility in Lauroglycol 90.
Construction of ternary phase diagram
Constructing phase diagrams is time consuming, 
particularly when the aim is to accurately delineate a phase 
boundary. Care was taken to ensure that observations are 
not made on metastable systems, although the free energy 
required to form an emulsion is very low, the formation is 
thermodynamically spontaneous (Craig et al., 1995). The 
relationship between the phase behaviour of a mixture and 
its composition can be captured with the aid of a phase 
diagram (Lawrence, Rees, 2000). LBF M 2125 CS and 
Maisine 35-1(1:1) as oil, Labrasol and Cremophor EL as 
surfactants and Lauroglycol 90 as cosurfactant, were put 
in separate Groups I and II to study the phase diagrams 
in detail. 
Group I 
In Group I, it can be observed that when surfactant 
was used alone without cosurfactant, [Smix ratio-1:0] 
(Figure 3A), very low amount of oil (13% v/v) could be 
solubilized at a high concentration (53% v/v) of surfactant. 
As the concentration of surfactant increased, solubilization 
of oil decreased. When surfactant and cosurfactant 
concentration was used in equal proportion [Smix ratio-1:1] 
(Figure 3B), it was observed that the nanoemulsion area 
decreased as compared to [Smix ratio-2:1] (Figure 3C), in 
which the nanoemulsion region in the phase diagram was 
found to be more and the oil solubilized upto 25% v/v 
with the Smix concentration of 48% v/v. When surfactant 
concentration was further increased to [Smix ratio-3:1] 
(Figure 3D), it was seen that nanoemulsion area decreased 
as compared to [Smix ratio-2:1] and only upto 15% v/v oil 
could be solubilized with a surfactant concentration of 
50% v/v. When the cosurfactant concentration was further 
increased to [Smix ratio-1:2] (Figure 3E), the maximum 
amount of oil that could be solubilized was 14% v/v and 
that too at a higher concentration of Smix (52% v/v). Further, 
cosurfactant concentration was increased to make [Smix 
ratio-1:3] in which very small area of nanoemulsion was 
obtained which was unstable and showed phase separation 
after 12 hours (data not shown). It can be observed that 
the formulations prepared from phase diagrams in which 
the nanoemulsion area was extended towards aqueous rich 
apex could be diluted to a larger extent.
Group II
In case of Group II, the o/w nanoemulsion area was 
limited when surfactant was used alone [Smix ratio-1:0] 
(Figure 4A). When cosurfactant was added along with 
surfactant in equal ratio [Smix ratio-1:1] (Figure 4B). 
There was slight improvement in nanoemulsion area, 
but it was not significant. It was observed in the phase 
diagram that 5% oil could be solubilized by 24% of Smix 
and 10 to 30% oil could be solubilized by just increasing 
Smix from 28 to 32% v/v. When cosurfactant concentration 
was doubled, Smix ratio 1:2 (Figure not shown), the total 
area of nanoemulsion decreased as compared to 1:1. In 
contrast, when surfactant concentration was increased 
as compared to cosurfactant, [Smix ratio 2:1] (Figure 4C), 
nanoemulsion region increased as compared to 1:1, giving 
an upward bulge in 10-20% oil concentration where the 
minimum Smix concentration required raised to 37%. 
Nevertheless, the maximum concentration of oil that 
could be solubilized by this ratio was 30% utilizing just 
35% v/v of Smix. When further surfactant concentration 
was increased to [Smix ratio-3:1] (Figure 4D), area of 
nanoemulsion decreased further and nanoemulsion gel 
TABLE II - Emulsification efficiency of various cosurfactants 
using surfactant labrasol and Cremophor EL and oily phases 
(LBF M 2125 CS + Maisine 35-1 (1:1)
Co-surfactants
% Transmittance
Labrasol Cremophor EL
Lauroglycol 90 97.4.4 95.4
Lauroglycol FCC 56.3 64
Caproyl 90 45.9 44.3
Propylene glycol 32.5 45.5
Polyethylene glycol 34.6 36.4
FIGURE 3 - Pseudo-ternary phase diagrams of Group I [Smix ratio 
= 1:0 (A), 1:1 (B), 2:1 (C), 3:1 (D), 1:2 (E)].
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area started coming in the phase diagram, which may be 
due to increased concentration of surfactant, although the 
maximum oil that could be solubilized by this ratio of Smix 
was 33% with just 36% v/v of Smix.
It was noticed that it took a little more time for 
achieving equilibrium to form nanoemulsion, which is 
obvious because of high concentration of oil solubilized by 
less concentration of Smix. Further increasing the Smix ratio 
to [Smix ratio-4:1] (Figure 4E), decreased nanoemulsion 
area but not to a large extend than 3:1, nanoemulsion 
area slowly decreased with increase in nanoemulsion gel 
area. The maximum concentration of oil that could be 
solubilized in 4:1 Smix ratio was 28% v/v with 37% v/v 
of Smix.
Thermodynamic stability studies
SNEDDS system undergoes in situ solubilization to 
form nanoemulsion system, and it should have stability 
such that it does not undergo precipitation, creaming or 
cracking. It is the thermostability which differentiates 
nanoemulsion from emulsions that have kinetic stability 
and will eventually phase separate (Shinoda et al., 1991). 
Therefore to check the stability, formulation was exposed 
to centrifugation, heating-cooling and freeze-thaw cycle. 
The formulations that passed these tests were selected for 
the dispersibility study in order to estimate the efficiency 
of dispersibility. Formulations selected from each 
phase diagram with their thermodynamic stability and 
dispersibility test are given in Table III and IV.
Dispersibility test
It is important that formed nanoemulsion in 
GIT should not undergo precipitation following phase 
separation with infinite dilution by GI fluids. It is observed 
more prominently with drugs having poor aqueous 
solubility or nanoemulsion which undergoes phase 
transition. To avoid such a situation, dispersibility studies 
in distilled water, in 0.1 N HCl and 6.8 phosphate buffers 
was vital. Formulations passing the dispersibility test in 
all the three media in grade A and B were considered to 
pass the dispersibility test. Since, these formulations were 
certain to form nanoemulsion upon dilution in the aqueous 
environment; these were selected for further study. 
Formulations selected after thermodynamic stability and 
dispersibility test are given in Table III and IV.
Interim stability study
In many cases, prolonged storage might cause the 
drug to precipitate from the nanoemulsion; seed crystals 
start to appear and might grow to large crystalline materials 
that will precipitate out at the bottom of the vessel (Parmar 
et al., 2011). Therefore, to check the stability, formulations 
were subjected to interim stability study.
Cloud point measurement
The cloud point is the temperature above, which 
the formulation clarity turns into cloudiness and is an 
essential factor in the formulation consisting of non-ionic 
surfactants. It is responsible for the successful formation 
of a stable nanoemulsion (Itoh et al., 2002). When the 
temperature is higher than the cloud point, an irreversible 
phase separation will occur and the cloudiness of the 
preparation would have a bad effect on drug absorption, 
because of the dehydration of the polyethylene oxide 
moiety (Yosra, Magda, Ossama, 2009). 
The cloud point value is affected by factors such as 
drug hydrophobicity, kind, combination, mixing ratio and 
amount of each of the oils, surfactants and cosurfactants 
used (Zhang et al., 2008). Since, both drug solubilization 
and formulation stability will decline with this phase 
separation, the cloud point of the formulation should be 
over 37 °C, which will avoid phase separation occurring 
in the GIT. Results (Table V) contented the stability of all 
formulations at physiological temperature in vivo. 
Percentage transmittance
SNEDDS form nanoemulsion in GIT, it meets with 
patient acceptability but isotropic nature of formulations 
or percentage transmittance closer to 100% gives an 
indication of globule size in nanometer range. Also, with 
increase in % transmittance closer to 100% lead to decrease 
in globule size of nanoemulsion formed as observed in 
case of LF3 (Table V). The droplet size of the emulsion is a 
crucial factor in self-emulsification performance, because 
it determines the rate and extent of drug release as well 
as absorption (Shah et al., 1994). Thus, the formulation 
FIGURE 4 - Pseudo-ternary phase diagrams of Group II [Smix 
ratio = 1:0 (A), 1:1 (B), 2:1 (C), 3:1 (D), 4:1 (E)].
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has the capacity to undergo enhanced absorption and thus 
ability to have increased oral bioavailability. 
Viscosity determination 
Viscosity studies are necessary for SNEDDS to 
characterize the system physically and to control its 
stability. The viscosity of all the formulations were 
determined (Table V). It was observed that the viscosity 
of LF3 was minimum, which may be due to the less oil 
content. 
Droplet size and polydispersity index
The droplet size of the nanoemulsion is important 
factor in SNEDDS formulation, as this determines the 
rate and extent of drug release as well as absorption. The 
PDI reflects the uniformity of particle diameter and can 
be used to depict the size distribution of nanoemulsion 
population. The smaller the droplet size, the larger 
the interfacial surface area will be provided for drug 
absorption (Gershanik, Benita, 2000; Kang et al., 2004). 
Moreover some authors have paid much attention to the 
TABLE III - Thermodynamic and dispersibility test of formulations selected from Group I at a difference of 5% v/v of oil
Smix Ratio 
(S:CoS)
%v/v of different 
components
Observations based on 
thermodynamic stability test
Observations based on 
dispersebility test Inference
Oil Smix Water H/C Cent Freez Water HCl PB
1:0 
(Fig. 3A)
10 48 42 √ X - - - - Fail
10 52 38 X - - - - - Fail
1:1 
(Fig. 3B)
10 48 42 X - - - - - Fail
10 52 38 √ √ √ A C - Fail
10 55 35 X - - - - - Fail
15 44 41 √ X - - - - Fail
15 50 35 √ √ √ A A A Pass*
15 55 30 √ √ √ B B B Pass
20 41 39 X - - - - - Fail
20 46 34 √ √ √ A A A Pass*
20 52 28 √ √ √ A B/C C Fail
25 48 27 √ X - - - - Fail
2:1 
(Fig. 3C)
10 40 50 X - - - - - Fail
10 50 40 √ √ √ A A A Pass
10 52 38 √ √ √ A A B Pass
15 44 41 √ X - - - - Fail
15 46 39 √ √ √ A A A Pass*
15 50 35 √ √ √ A A/B A Pass
20 52 28 √ √ √ A A/B A Pass*
20 54 26 √ √ √ A A/B B Pass
20 56 24 √ √ √ B C - Fail
25 48 27 √ √ √ A A A Pass*
3:1 
(Fig. 3D)
10 40 50 √ X - - - - Fail
10 44 46 √ √ √ A B C Fail
10 48 42 √ √ √ B C - Fail
15 50 35 √ √ X - - - Fail
1:2 
(Fig. 3E)
10 45 45 √ √ √ D - - Fail
10 52 38 √ X - - - - Fail
H/C- Heating cooling cycle; Cent- Centrifugation; Freez- Freeze thaw cycle; *Formulation selected
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TABLE IV - Thermodynamic dispersibility test of formulations selected from Group II at a difference of 5% v/v of oil
Smix Ratio 
(S:CoS)
%v/v of different components
Observations based on 
thermodynamic stability test
Observations based on 
dispersebility test Inference
Oil Smix Water H/C Cent Freez Water HCl PB
2:1 
(Fig. 4C)
10 35 55 X - - - - - Fail
10 42 48 √ √ √ A C A Fail
10 48 42 √ √ √ C - - Fail
15 44 46 √ X - - - - Fail
15 45 40 √ √ √ A A A Pass*
15 50 35 √ √ √ A A A/B Pass
20 42 38 √ √ √ A A A Pass*
20 45 35 √ √ √ A A A Pass
20 48 32 √ √ √ A A A/B Pass
25 28 47 √ √ √ A A A Pass*
25 32 43 √ √ √ A A B Pass
25 47 28 √ √ √ C - - Fail
30 30 40 X - - - - - Fail
30 35 35 √ √ √ D - - Fail
3:1 
(Fig. 4D)
10 40 50 X - - - - - Fail
10 48 42 √ √ √ C - - Fail
10 54 36 √ √ √ B B C Fail
15 44 41 √ √ √ A A A Pass*
15 45 40 √ √ √ A A A Pass
15 52 33 √ X - - - - Fail
20 32 48 X - - - - - Fail
20 40 40 √ √ √ A A A Pass*
20 52 28 √ √ √ A A A Pass
25 32 43 √ X - - - - Fail
25 35 40 √ √ √ B C - Fail
25 42 33 √ √ √ A A A Pass*
30 28 42 √ √ X - - - Fail
30 30 40 √ √ √ D - - Fail
30 36 34 X - - - - - Fail
4:1 
(Fig. 4E)
10 40 50 X - - - - - Fail
10 48 42 √ √ √ B C - Fail
10 54 36 √ √ √ D - - Fail
15 40 45 X - - - - - Fail
15 48 37 √ √ √ C - - Fail
15 52 33 √ √ √ Pass
20 30 50 X - - - - - Fail
20 33 47 √ √ X - - - Fail
20 48 32 √ √ √ B A D Fail
25 32 43 √ √ √ D - - Fail
25 35 40 X - - - - - Fail
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drug solubilization capacity in the lipid formulations when 
dilution and digestion in the GIT, which would influence 
the subsequent dispersion and absorption of drug (Gao et 
al., 2003; Kossena et al., 2004; Porter et al., 2004). 
The droplet size distribution of all the formulations 
is given in Table V. The formulations were in nanometer 
size range (24.8 nm - 59.7 nm). A decrease in the content 
of the oil phase resulted in a proportional decrease in 
particle size, because of the simultaneous increase in the 
Smix proportion. The droplet size and polydispersity index 
were minimum in the case of LF3 (Figure 5) suggesting 
uniformity in the droplet size. 
In vitro release study
Three formulations were selected from each 
group having smallest droplet size, least viscosity and 
polydispersity, higher percentage transmittance and 
cloud point. The studies were performed to evaluate 
the sertraline release characteristics from developed 
SNEDDS. The highest release of sertraline (97%) was 
observed in case of LF3 (Figure 6). This was because of 
small globule size, and eventually higher surface area 
in case of nanoemulsions, which permit faster rate of 
drug release. Thus, this greater availability of dissolved 
sertraline from the SNEDDS formulation could lead to 
higher absorption and oral bioavailability.
Optimization of solid SNEDDS 
It was observed that solid adsorbents such as dibasic 
calcium phosphate, anhydrous lactose, calcium carbonate, 
magnesium carbonate did not have good adsorption 
capacity. Aerosil 200 exhibited good adsorption (1:2 ratio), 
excellent flow properties and optimum bulk density to 
FIGURE 5 - Particle size distribution of LF3 formulation at 24 
h post dilution with distilled water using Malvern Zetasizer.
TABLE V - Droplet size, polydispersity index, viscosity, percentage transmittance and cloud point of liquid SNEDDS
Formulation %Oil %S %CoS Interim Stability
Droplet
Size ± SD 
(nm)
PDI* Viscosity ± SD (cP) % T**
Cloud Point 
(°C)
LF1 23.07 38.46 38.46 Unstable - - - - -
LF2 30.30 34.85 34.85 Stable 52.53 ± 1.45 0.344 185.43 ± 1.84 75.25 72
LF3 24.59 50.27 25.13 Stable 24.8 ± 0.32 0.182 153.63 ± 2.14 95.00 82
LF4 27.77 48.15 24.07 Stable 34.3 ± 1.41 0.245 162.46 ± 1.84 90.33 76
LF5 34.25 43.83 21.92 Stable 39.3 ± 0.72 0.282 172.45 ± 2.54 87.43 74
CF1 25 50 25 Stable 45.36 ± 0.62 0.211 162.42 ± 1.74 85.46 80
CF2 32.26 45.16 22.58 Stable 49.54 ± 0.82 0.224 168.44 ± 1.61 83.44 70
CF3 47.16 35.22 17.61 Stable 59.7 ± 0.54 0.434 178.34 ± 1.42 75.52 62
CF4 25.42 55.93 18.64 Stable 44.42 ± 0.64 0.199 158.44 ± 2.34 93.30 82
CF5 33.33 50 16.66 Stable 45.64 ± 0.52 0.218 166.34 ± 1.63 88.66 84
CF6 37.31 47.01 15.67 Unstable - - - - -
*polydispersity index, **percentage transmittance
FIGURE 6 - Dissolution profile of optimized liquid SNEDDS. 
Data are expressed as mean (n = 3).
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be compressed into tablets. Briefly, solid SNEDDS was 
prepared containing a fixed proportion of sertraline 25 mg 
(single dose) dissolved in a mixture of oily liquid (59.58% 
w/w), mixed with Aerosil (34.42% w/w), sodium starch 
glycolate (5% w/w) and magnesium stearate (1% w/w). 
Angle of repose of solid SNEDDS was 24.85 ± 0.02, 
Carr’s index was found to be 11.14 ± 0.43%, Hausner’s 
ratio was 1.13 ± 0.01 which indicated good flow properties 
of solid SNEDDS.
Reconstituting properties and physical 
characterization 
The solid SNEDDS preserved the self-emulsification 
performance of the liquid SNEDDS and on reconstitution 
in distilled water yielded nanoemulsion with globule size 
of 30.7 nm, which was similar with the droplet size of 
liquid SNEDDS (24.8 nm) with a polydispersity index 
of 0.163. The globule size of the nanoemulsion slightly 
increased after adsorption of liquid formulation over 
Aerosil, but the difference was not statistically significant 
(p>0.05).
The physical state of sertraline in the solid 
SNEDDS was verified by X-ray powder diffractograms 
(Figure 7), since it would have an important influence 
on the in vitro and in vivo release characteristics. Due 
to the dilution by Aerosil, sodium starch glycolate 
and magnesium stearate a few peaks appeared in the 
physical mixture of sertraline and Aerosil, sodium starch 
glycolate, magnesium stearate (curve B). No obvious 
peaks representing crystals of sertraline were seen for 
the solid SNEDDS (curve C). 
In vitro comparative release study
Release study was performed to compare the release 
of sertraline from optimized liquid and solid SNEDDS 
(tablet) with the release from plain sertraline. The release 
of sertraline from solid SNEDDS was 94.3%, significantly 
higher (p<0.01) compared with the plain sertraline (Figure 
8). However, the release rate and extent of liquid SNEDDS 
was slightly higher than that of the solid SNEDDS. Three 
reasons may probably explain the result. Firstly, there is a 
disintegration process for the tablets, which will delay the 
first step of drug release. Secondly, the excipients such as 
Aerosil will have a relatively strong interaction with the 
adsorbed SNEDDS. Third reason may be due to slight 
increase in droplet size after reconstitution which provides 
smaller surface area, probably impairing the release rate 
and extent of sertraline. 
In vivo study 
The plasma concentrations vs. time profiles are 
shown in Figure 9, and the pharmacokinetic parameters are 
summarized in Table VI. Dosing the aqueous suspensions 
of sertraline resulted in the lowest average sertraline 
plasma concentrations. However, the AUC0-t was about 
6-and 5-times greater when sertraline was administered 
as liquid and solid SNEDDS, compared with the AUC0-t 
obtained for the aqueous suspension of sertraline. 
The liquid and solid SNEDDS gave mean values 
of Cmax 220.51 ng/mL and 209.62 ng/mL, which were 
17.75- and 16.87-fold higher than the Cmax obtained with 
the same dose of sertraline administered as an aqueous 
suspension (12.42 ng/mL). The Tmax of both the liquid (1.0 
h) and solid SNEDDS (1.83 h) was significantly lower 
FIGURE 8 - Release patterns of sertraline loaded liquid (LF3) 
and solid SNEDDS compared to that from plain sertraline. Data 
are expressed as mean (n = 3).
FIGURE 7 - X-ray powder diffractometry of (A) pure sertraline, 
(B) physical mixture, and (C) solid SNEDDS.
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than Tmax obtained with aqueous suspension of sertraline 
(5.92 h). Also, the optimized formulations showed greater 
improvement in relative bioavailability compared to 
aqueous suspension of sertraline. These results reveal that 
formulations of sertraline as liquid and solid SNEDDS 
results in a significantly increased absorption, compared 
with that from the aqueous suspension of plain sertraline.
The improved absorption of sertraline was probably 
due to the enhanced solubilization. Sertraline dissolved in 
liquid and solid adsorb powder could be directly absorbed 
as the nanoemulsion droplets in the GIT, without a 
dissolution step. The small droplet size of less than 50 nm 
of oil-in-water nanoemulsions might penetrate the site of 
absorption via transcellular pathway.
The oil used in the formulations is probably to 
protect the drug from enzyme degradation (Gursoya, 
Benita 2004). Nonionic surfactants not only improved 
the solubility and dissolution of the drug may also reduce 
the interfacial surface tension and enhance penetration of 
the drug through the epithelial cells. In addition, Labrasol 
has been reported to increase tight junction permeability 
(Lindmark et al., 1995), leading to enhanced drug 
absorption by paracellular pathway. The pharmacokinetic 
data in male SD rats imply that SNEDDS in both liquid and 
solid formulation developed in this study could improve 
dissolution and absorption of sertraline.
CONCLUSION
The present study demonstrated that both the liquid 
and solid SNEDDS were successfully developed. The 
optimized formulation readily released the lipid phase 
to form a fine oil-in-water nanoemulsion, with a narrow 
size distribution. Tablets were able to carry SNEDDS and 
possess acceptable pharmacopeia requirements for tablets. 
In addition, they were able to introduce the SNEDDS into 
the dissolution media where it was efficiently transformed 
into nanoemulsion by the gentle agitation provided in the 
dissolution experiment. Modifying Aerosil physical from 
amorphous into granules improved the physical properties 
of both liquisolid powders and tablets. It enhanced the 
adsorption power and compressibility of liquisolid 
tablets. The oral absorption of sertraline from both the 
formulations was much greater than the plain sertraline. 
Successfully, SNET were able to introduce sertraline in 
a unique immediate-release dosage form with improved 
bioavailability. 
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FIGURE 9 - Mean plasma concentration profile of sertraline 
after oral administration of liquid (LF3) and solid SNEDDS, 
aqueous suspension of plain sertraline. Data are expressed as 
mean (n = 3).
TABLE VI - Relative bioavailability and pharmacokinetics parameters after oral administration of liquid (LF3) and solid SNEDDS, 
aqueous suspension of plain sertraline. All values reported are mean ± SD (n = 3)
Formulations Tmax
a 
(h)
Cmaxb 
(ng/mL)
AUC0 → tc 
(ng.h/mL)
Relative 
Bioavailability (%)
Liquid SNEDDS (LF3) 1.0 ± 0.26* 220.51 ± 27.53** 1072.89 ± 283.5** 589.08†
Solid SNEDDS 1.83 ± 0.35* 209.62 ± 19.16** 917.99 ± 263.7** 504.03†
Aq. suspension of sertraline 5.92 ± 0.47 12.42 ± 2.65 182.13 ± 32.65 -
* p<0.01 and ** p<0.001 when compared with aq. suspension of sertraline using one way ANOVA; a time of peak concentration; b 
peak of maximum concentration; c area under the concentration time profile curve until last observation; † relative bioavailability 
compared to aq. suspension of plain sertraline.
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